A5175: A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICAC

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypotheses: Three-drug antiretroviral (ARV) regimens administered once-daily and twice-daily provide similar ARV benefit in resource-limited settings for HIV-1- infected persons with CD4+ cell counts <300 cells/mm3. A three-drug ARV regimen containing a protease inhibitor (PI), administered once-daily, provides similar ARV benefit in resource-limited settings for HIV-1-infected persons with CD4+ cell counts <300 cell/mm3 as compared with a three-drug ARV regimen administered twice daily that contains an non-nucleosis reverse transcriptase (NNRTI).